$FDMT

About Us

This page from WaterWorld provides the latest news and stock information for 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT). It lists recent company announcements, financial results, clinical trial updates for gene therapies, and participation in investor conferences. The content includes details on stock performance and links to various news sources like MarketBeat, GlobeNewswire, and Benzinga.

Original reporting
Published May 18, 2026, 4:39 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 18, 2026, 5:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About Us — source image
Decision brief

The 30-second read

$FDMTNeutralLow
01

Why it matters

The news may support short-term investor confidence but does not indicate immediate major breakthroughs or setbacks.

02

Market read

The news is relevant to biotech investors and stakeholders interested in gene therapy developments, with limited broader market impact.

03

What to watch

Broader market conditions, regulatory developments, and competitor activities could significantly influence stock performance beyond the news content.

Timing: short-term (within days to weeks)

Background

4D Molecular Therapeutics is engaged in developing gene therapies, with recent updates on clinical trials and financial performance.

Company-level read

Ticker impact

$FDMTNeutralMedium confidence
Context

The news pertains directly to 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), providing recent updates on company activities, financial results, and clinical trials.

Expected impact

Potential slight upward movement in the short term, approximately 2-3%, contingent on clinical trial outcomes and investor sentiment.

Evidence & confidence

The information is current and company-specific, but the overall market response remains uncertain until trial results are announced.

Market effects

The company's activities in gene therapies and clinical trials could positively influence the biotech sector, especially companies involved in similar therapeutic areas.

Limited regional impact; primarily affects investors and stakeholders within the U.S. biotech market.

Minimal; the news is specific to a U.S.-based biotech company with limited immediate global market implications.

Counterpoint

The neutral news could be a sign that the company is in a wait-and-see phase, and any unexpected negative trial results could lead to a decline.

Key entities

  • 4D Molecular Therapeutics, Inc.

    A biotech firm specializing in gene therapies, listed on Nasdaq as FDMT.

Related articles

$FDMTMedAI 8/10

4DMT reports new phase 2b gene therapy data for wet AMD

4D Molecular Therapeutics reported positive 2-year results from its phase 2b PRISM trial of 4D-150 for wet age-related macular degeneration. The company said the study showed sustained BCVA and OCT central subfield thickness improvements and reduced treatment burden versus projected on-label aflibercept. Safety was described as well tolerated, with 2.8% mild transient inflammation. Phase 3 topline data is expected in 2027.

$FDMTMed

Why Is 4D Molecular Therapeutics Stock Gaining Monday? - 4D Molecular Therapeutics (NASDAQ:FDMT)

4D Molecular Therapeutics (FDMT) shares rose after Phase 2b results for 4D-150 in wet AMD. In 45 patients, the 3E10 vg/eye dose was chosen for Phase 3. As of May 18, 2026, it maintained visual acuity and reduced treatment burden 78% vs projected aflibercept injections, with 2.8% mild inflammation. Phase 3 enrollment completed; topline expected 2027. HC Wainwright reiterated Buy, $36 target.

$RKLBMedAI 8/10

Rocket Lab Just Unveiled a Game-Changing Technology Worth Watching

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).